Kowa Company, Ltd. – Product Pipeline Review – 2012
SUMMARY
Global Market Direct’s pharmaceuticals report, “Kowa Company, Ltd. Product Pipeline Review - 2012” provides data on the Kowa Company, Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Kowa Company, Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Kowa Company, Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
SCOPE
SUMMARY
Global Market Direct’s pharmaceuticals report, “Kowa Company, Ltd. Product Pipeline Review - 2012” provides data on the Kowa Company, Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Kowa Company, Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Kowa Company, Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
SCOPE
- Kowa Company, Ltd. - Brief Kowa Company, Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Kowa Company, Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Kowa Company, Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Kowa Company, Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Kowa Company, Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Kowa Company, Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Kowa Company, Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Kowa Company, Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Kowa Company, Ltd. and identify potential opportunities in those areas.
Kowa Company, Ltd. Snapshot
Kowa Company, Ltd. Overview
Key Information
Key Facts
Kowa Company, Ltd. – Research and Development Overview
Key Therapeutic Areas
Kowa Company, Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Kowa Company, Ltd. – Pipeline Products Glance
Kowa Company, Ltd. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Kowa Company, Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Kowa Company, Ltd. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Kowa Company, Ltd. – Drug Profiles
epirubicin hydrochloride
Product Description
Mechanism of Action
R&D Progress
K-04C
Product Description
Mechanism of Action
R&D Progress
K-115
Product Description
Mechanism of Action
R&D Progress
K-134
Product Description
Mechanism of Action
R&D Progress
K-604
Product Description
Mechanism of Action
R&D Progress
K-828-AB
Product Description
Mechanism of Action
R&D Progress
K-877
Product Description
Mechanism of Action
R&D Progress
peretinoin
Product Description
Mechanism of Action
R&D Progress
Pitavastatin Calcium
Product Description
Mechanism of Action
R&D Progress
SK-0403
Product Description
Mechanism of Action
R&D Progress
Kowa Company, Ltd. – Pipeline Products by Therapeutic Class
Kowa Company, Ltd. – Pipeline Products by Route of Administration
Kowa Company, Ltd. – Pipeline Products By Mechanism of Action
Kowa Company, Ltd. – Recent Pipeline Updates
Kowa Company, Ltd. - Dormant Projects
Kowa Company, Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ketoprofen
Kowa Company, Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Kowa Company, Ltd., Recent Developments
Kowa Company, Ltd.- Press Release
Jun 06, 2012: Tai Tien Pharma Launches Pitavastatin Calcium In Taiwan
May 31, 2012: Kowa And Lilly Announce Phase IV Study Results Of Livalo In Patients With Primary Hyperlipidemia
Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134
Dec 23, 2009: Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement; Companies to co-promote newly-approved statin Livalo in the U.S. market. Lilly licenses Livalo commercialization rights for Latin America
Aug 03, 2009: FDA Approves Livalo for Primary Hypercholesterolemia and Combined Dyslipidemia
Financial Deals Landscape
Kowa Company, Ltd., Deals Summary
Kowa Company, Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Eli Lilly Enters Into Co-Marketing Agreement With Kowa Pharma
Recordati Enters Into Agreement With Kowa Pharma
Teva Pharma Industries Signs Joint Venture Agreement With Kowa Company
Licensing Agreements
Kowa Company Enters Into Licensing Agreement With Abbott
NanoCarrier Enters Into Licensing Agreement With Kowa Company For NC-6300
Eli Lilly Enters Into Licensing Agreement Kowa Pharma
Kowa Enters Into A Licensing Agreement With Taiwan Tanabe Seiyaku And P.T. Tanabe Indonesia
SANWA KAGAKU KENKYUSHO Enters Into Licensing Agreement With Kowa Company
Asset Transactions
Nautilus Neurosciences Acquires Diclofenac Products From Kowa Pharma
Acquisition
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For $150 Million
Kowa Company Completes Acquisition Of ProEthic Pharma
Kowa Company Acquires Additional 38% Stake In Nikken Chemicals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Kowa Company, Ltd., Key Information
Kowa Company, Ltd., Key Facts
Kowa Company, Ltd. – Pipeline by Indication, 2012
Kowa Company, Ltd. – Pipeline by Stage of Development, 2012
Kowa Company, Ltd. – Monotherapy Products in Pipeline, 2012
Kowa Company, Ltd. – Filed, 2012
Kowa Company, Ltd. – Phase III, 2012
Kowa Company, Ltd. – Phase II, 2012
Kowa Company, Ltd. – Phase I, 2012
Kowa Company, Ltd. – Pre-Clinical, 2012
Kowa Company, Ltd. – Pipeline By Therapeutic Class, 2012
Kowa Company, Ltd. – Pipeline By Route of Administration, 2012
Kowa Company, Ltd. – Pipeline Products By Mechanism of Action, 2012
Kowa Company, Ltd. – Recent Pipeline Updates, 2012
Kowa Company, Ltd. - Dormant Developmental Projects,2012
Kowa Company, Ltd. - Discontinued Pipeline Products, 2012
Kowa Company, Ltd., Other Locations
Kowa Company, Ltd., Subsidiaries
Kowa Company, Ltd., Deals Summary
Eli Lilly Enters Into Co-Marketing Agreement With Kowa Pharma
Recordati Enters Into Agreement With Kowa Pharma
Teva Pharma Industries Signs Joint Venture Agreement With Kowa Company
Kowa Company Enters Into Licensing Agreement With Abbott
NanoCarrier Enters Into Licensing Agreement With Kowa Company For NC-6300
Eli Lilly Enters Into Licensing Agreement Kowa Pharma
Kowa Enters Into A Licensing Agreement With Taiwan Tanabe Seiyaku And P.T. Tanabe Indonesia
SANWA KAGAKU KENKYUSHO Enters Into Licensing Agreement With Kowa Company
Nautilus Neurosciences Acquires Diclofenac Products From Kowa Pharma
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For $150 Million
Kowa Company Completes Acquisition Of ProEthic Pharma
Kowa Company Acquires Additional 38% Stake In Nikken Chemicals
List of Figures
Kowa Company, Ltd. – Pipeline by Indication, 2012
Kowa Company, Ltd. – Pipeline by Stage of Development, 2012
Kowa Company, Ltd. – Monotherapy Products in Pipeline, 2012
Kowa Company, Ltd. - Pipeline Products By Mechanism of Action, 2012
Kowa Company, Ltd. Overview
Key Information
Key Facts
Kowa Company, Ltd. – Research and Development Overview
Key Therapeutic Areas
Kowa Company, Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Kowa Company, Ltd. – Pipeline Products Glance
Kowa Company, Ltd. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Kowa Company, Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Kowa Company, Ltd. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Kowa Company, Ltd. – Drug Profiles
epirubicin hydrochloride
Product Description
Mechanism of Action
R&D Progress
K-04C
Product Description
Mechanism of Action
R&D Progress
K-115
Product Description
Mechanism of Action
R&D Progress
K-134
Product Description
Mechanism of Action
R&D Progress
K-604
Product Description
Mechanism of Action
R&D Progress
K-828-AB
Product Description
Mechanism of Action
R&D Progress
K-877
Product Description
Mechanism of Action
R&D Progress
peretinoin
Product Description
Mechanism of Action
R&D Progress
Pitavastatin Calcium
Product Description
Mechanism of Action
R&D Progress
SK-0403
Product Description
Mechanism of Action
R&D Progress
Kowa Company, Ltd. – Pipeline Products by Therapeutic Class
Kowa Company, Ltd. – Pipeline Products by Route of Administration
Kowa Company, Ltd. – Pipeline Products By Mechanism of Action
Kowa Company, Ltd. – Recent Pipeline Updates
Kowa Company, Ltd. - Dormant Projects
Kowa Company, Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ketoprofen
Kowa Company, Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Kowa Company, Ltd., Recent Developments
Kowa Company, Ltd.- Press Release
Jun 06, 2012: Tai Tien Pharma Launches Pitavastatin Calcium In Taiwan
May 31, 2012: Kowa And Lilly Announce Phase IV Study Results Of Livalo In Patients With Primary Hyperlipidemia
Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134
Dec 23, 2009: Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement; Companies to co-promote newly-approved statin Livalo in the U.S. market. Lilly licenses Livalo commercialization rights for Latin America
Aug 03, 2009: FDA Approves Livalo for Primary Hypercholesterolemia and Combined Dyslipidemia
Financial Deals Landscape
Kowa Company, Ltd., Deals Summary
Kowa Company, Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Eli Lilly Enters Into Co-Marketing Agreement With Kowa Pharma
Recordati Enters Into Agreement With Kowa Pharma
Teva Pharma Industries Signs Joint Venture Agreement With Kowa Company
Licensing Agreements
Kowa Company Enters Into Licensing Agreement With Abbott
NanoCarrier Enters Into Licensing Agreement With Kowa Company For NC-6300
Eli Lilly Enters Into Licensing Agreement Kowa Pharma
Kowa Enters Into A Licensing Agreement With Taiwan Tanabe Seiyaku And P.T. Tanabe Indonesia
SANWA KAGAKU KENKYUSHO Enters Into Licensing Agreement With Kowa Company
Asset Transactions
Nautilus Neurosciences Acquires Diclofenac Products From Kowa Pharma
Acquisition
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For $150 Million
Kowa Company Completes Acquisition Of ProEthic Pharma
Kowa Company Acquires Additional 38% Stake In Nikken Chemicals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Kowa Company, Ltd., Key Information
Kowa Company, Ltd., Key Facts
Kowa Company, Ltd. – Pipeline by Indication, 2012
Kowa Company, Ltd. – Pipeline by Stage of Development, 2012
Kowa Company, Ltd. – Monotherapy Products in Pipeline, 2012
Kowa Company, Ltd. – Filed, 2012
Kowa Company, Ltd. – Phase III, 2012
Kowa Company, Ltd. – Phase II, 2012
Kowa Company, Ltd. – Phase I, 2012
Kowa Company, Ltd. – Pre-Clinical, 2012
Kowa Company, Ltd. – Pipeline By Therapeutic Class, 2012
Kowa Company, Ltd. – Pipeline By Route of Administration, 2012
Kowa Company, Ltd. – Pipeline Products By Mechanism of Action, 2012
Kowa Company, Ltd. – Recent Pipeline Updates, 2012
Kowa Company, Ltd. - Dormant Developmental Projects,2012
Kowa Company, Ltd. - Discontinued Pipeline Products, 2012
Kowa Company, Ltd., Other Locations
Kowa Company, Ltd., Subsidiaries
Kowa Company, Ltd., Deals Summary
Eli Lilly Enters Into Co-Marketing Agreement With Kowa Pharma
Recordati Enters Into Agreement With Kowa Pharma
Teva Pharma Industries Signs Joint Venture Agreement With Kowa Company
Kowa Company Enters Into Licensing Agreement With Abbott
NanoCarrier Enters Into Licensing Agreement With Kowa Company For NC-6300
Eli Lilly Enters Into Licensing Agreement Kowa Pharma
Kowa Enters Into A Licensing Agreement With Taiwan Tanabe Seiyaku And P.T. Tanabe Indonesia
SANWA KAGAKU KENKYUSHO Enters Into Licensing Agreement With Kowa Company
Nautilus Neurosciences Acquires Diclofenac Products From Kowa Pharma
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For $150 Million
Kowa Company Completes Acquisition Of ProEthic Pharma
Kowa Company Acquires Additional 38% Stake In Nikken Chemicals
List of Figures
Kowa Company, Ltd. – Pipeline by Indication, 2012
Kowa Company, Ltd. – Pipeline by Stage of Development, 2012
Kowa Company, Ltd. – Monotherapy Products in Pipeline, 2012
Kowa Company, Ltd. - Pipeline Products By Mechanism of Action, 2012
